Co-Diagnostics Targets India TB Test Launch. Co-Diagnostics announced plans to commercialize its tuberculosis diagnostic test in India by the third quarter of 2026, marking a significant expansion into one of the world's largest markets for TB diagnostics. The company faces considerable cash burn concerns that have prompted management to explore strategic alternatives, including potential SPAC merger opportunities for its CoSara subsidiary. Additionally, the company shifted its FDA submission timeline for combined flu and RSV diagnostic tests, adjusting its regulatory strategy to better align with market demands and internal resource allocation. These developments reflect management's efforts to balance growth ambitions with financial sustainability in a competitive diagnostic testing landscape.
Post from MarketNews_en
Log in to interact with content.